CirculationHumansDouble-Blind MethodMaleFemaleAntibodies
Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial.
Marianna Fontana, Pablo García-Pavía, Martha Grogan, Sanjiv J Shah, Mads D M Engelmann, G Kees Hovingh, Arnt V Kristen, Michelle Z Lim-Watson, Brian Malling, Soumitra Kar, Manjunatha Revanna, Nitasha Sarswat, Kenichi Tsujita, Kevin M Alexander, Mathew S Maurer
Published: 202610.1161/CIRCULATIONAHA.125.077304
Abstract
BACKGROUND: Transthyretin amyloidosis with cardiomyopathy is a progressive disease caused by the deposition of transthyretin (TTR) as amyloid in the myocardium. Current therapies may slow disease progression but do not clear existing deposits. Corami…
Preview only. Read the full abstract at the source